NLS Pharmaceutics

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness (EDS) and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder (ADHD). The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.

ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, CEO and Co-Founder, will participate in a fireside chat at the B.

NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference

ZURICH, SWITZERLAND / ACCESSWIRE / April 13, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorder, today announced that it has entered into definitive agreements with health-care focused institutional investors alongside participation from the Company's Chairman of the Board of Directors, Ronald Hafner, for the purchase and sale of 4,200,000 of the Company's common shares (or common share equivalents) at a purchase price of $1.04 per common share (or common share equivalent) in a registered direct offering priced at-the-market under Nasdaq rules.

NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ZURICH, SWITZERLAND / ACCESSWIRE / April1, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has received a letter from the Listing Qualifications staff of The Nasdaq Stock Market ("Nasdaq") notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.

NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements

ZURICH, SWITZERLAND / ACCESSWIRE / March 31, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has retained LifeSci Partners as financial advisor to assist the Company in evaluating a variety of strategic partnering initiatives.

NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives

Named Patient Program (NPP) enables physicians to prescribe the Company's novel Mazindol Extended-Release (ER) formulation to patients who have failed approved therapies Product sales through the NPP are expected to be revenue-generating, with patient access anticipated to begin in Q2 2022 ZURICH, SWITZERLAND / ACCESSWIRE / March 28, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has entered into an agreement with Caligor Coghlan Pharma Services (CCPS) to administer a Named Patient Program enabling European patients with Idiopathic Hypersomnia (IH) to have pre-approval access to treatment with the Company's novel Mazindol ER formulation.

NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER

ZURICH, SWITZERLAND / ACCESSWIRE / March 25, 2022 - NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, CEO and Co-Founder, will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference, being held March 28-30, 2022.

NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference

NLS Pharmaceutics Ltd (NASDAQ: NLSP) has announced interim topline data from its Phase 2a trial of its lead product candidate, Quilience (Mazindol ER), in narcolepsy.  For excessive daytime sleepiness (EDS), the trial's primary endpoint, patients on Mazindol ER exhibited a.

NLS Pharma Shares Fall After Mazindol ER Interim Data Shows 39% Improvement On Sleepiness Scale

Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline (-4.3 points placebo-adjusted); confirms statistical powering of the ongoing Phase 2a trial Safety and tolerability data consistent with prior mazindol clinical trials, no reported SAEs 82% of patients that completed the randomized trial to date have rolled over into the open label extension (OLE) study Majority of patients that enrolled in the OLE (both NT1 and NT2) remain in the study and on Mazindol ER monotherapy ZURICH, SWITZERLAND / ACCESSWIRE / March 16, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces positive interim top-line data from its Phase 2a clinical trial evaluating its lead product candidate, Quilience® (Mazindol ER), in the treatment of narcolepsy.

NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy

Akebia Therapeutics

Globalstar

Penny stocks for your watch list this month. The post 3 Penny Stocks To Watch For Your List In March 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Watch For Your List In March 2022

ZURICH, SWITZERLAND / ACCESSWIRE / February 25, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP) (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, will be available for one-on-one meetings with conference attendees at the SACHS 15th Annual European Life Sciences Virtual CEO Forum taking place March 1-2, 2022.

NLS Pharmaceutics to Participate in the SACHS 15th Annual European Life Sciences Virtual CEO Forum and a Fireside Chat with Maxim Analyst in March

ZURICH, SWITZERLAND / ACCESSWIRE / February 11, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, will be available for one-on-one meetings with conference attendees.

NLS Pharmaceutics to Participate in 2022 BIO CEO & Investor Conference

NLS Pharmaceutics Ltd NLSP shares are trading higher after the Company announced to present interim topline data from its Phase 2a trial evaluating its lead product candidate, Quilience (Mazindol ER), for narcolepsy at World Sleep Congress 2022. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Why Are NLS Pharmaceutics Shares Trading Higher During Premarket Monday?

Phase 2a trial meets enrollment target for interim analysis and is now more than 50% enrolled 21 clinical sites in the United States actively enrolling patients Nearly 90% of patients completing the trial have opted into the Open Label Extension study ZURICH, SWITZERLAND / ACCESSWIRE / February 7, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it will present interim top-line data from its Phase 2a clinical trial evaluating its lead product candidate, Quilience® (Mazindol ER), for the treatment of narcolepsy at this year's World Sleep Congress (World Sleep 2022), taking place in Rome, Italy March 11-16, 2022.

NLS Pharmaceutics to Present Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022

ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Wake Up Narcolepsy, a leading patient advocacy organization dedicated to serving the narcolepsy community, will host an online International Narcolepsy Webinar taking place on January 20-21, 2022.

NLS Pharmaceutics Invites Patients, Caregivers and Other Interested Parties to Attend International Narcolepsy Webinar

Data Storage Corp

Here are three penny stocks to add to your watchlist for next week The post 3 Penny Stocks to Watch in the Second Week of January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch in the Second Week of January

The stock price of NLS Pharmaceutics AG (NASDAQ: NLSP) increased by over 80% during intraday trading today. This is why it happened.

NLS Pharmaceutics Stock (NLSP) Why The Price Surged Today

Key patent now granted in major markets including the U.S., Europe, Canada & South Korea Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention deficit hyperactivity disorder (ADHD) & narcolepsy STANS, SWITZERLAND / ACCESSWIRE / January 4, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent No.

NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation

STANS, SWITZERLAND / ACCESSWIRE / November 30, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces final results from a preclinical study for NLS-4 (Lauflumide), the Company's next-generation wake-promoting drug candidate.

NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model

STANS, SWITZERLAND / ACCESSWIRE / October 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces preclinical data for NLS-4 (Lauflumide), the Company's next-generation wake-promoting drug candidate, which has shown promise for the treatment of chronic fatigue associated with Long-COVID (also known as "chronic COVID syndrome").

NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID

STANS, SWITZERLAND / ACCESSWIRE / September 30, 2021 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that its Chief Executive Officer and Co-Founder Alex Zwyer is scheduled to present a corporate overview and meet with investors at The Micro Cap Rodeo Fall Harvest Conference to be held virtually October 5-8, 2021.

NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side

STANS, SWITZERLAND / ACCESSWIRE / September 28, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has entered into a standby equity distribution agreement, or SEDA, with YA II PN, Ltd.

NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment

STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the initiation of its Phase 2 clinical trial evaluating Quilience® (mazindol extended release or "ER") as a once-daily monotherapy for the treatment of excessive daytime sleepiness (EDS) and cataplexy, the primary symptoms of narcolepsy.

NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled

STANS, SWITZERLAND / ACCESSWIRE / September 8, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present a corporate overview and participate in meetings with investors at the H.C.

NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference

The shares of NLS Pharmaceutics Ltd. (NASDAQ:NLSP) increased by over 30% intraday.

NLS Pharmaceutics Shares Increase Over 30% Intraday: Why It Happened

Senseonics Holdings

Sonnet BioTherapeutics

Looking to buy penny stocks in 2021? Check these 3 out for your list The post Buying Penny Stocks Right Now?

News for NLS Pharmaceutics Stock (NLSP)